A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN 0701)

Trial Profile

A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN 0701)

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary) ; Methotrexate; Tacrolimus
  • Indications Follicular lymphoma; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2013 Planned end date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned end date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by (M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top